ABSTRACT
OBJECTIVE To synthesize[3H]labelled trantinterol and determine the mass balance in rats and the profile of trantinterol and its metabolites in excreta. METHODS [3H]Trantinterol was synthesised from the intermediate1-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-bromo-ethanone through reduction by sodium borotritide and aminolysis by t-butylamine. Following an oral dose of[3H] trantinterol(45.5 MBq·kg-1)to bile duct cannulated(BDC)rats and normal rats. Bile,urine and faeces were collected individually before and after dosing at different times. Liquid scintillation counter(LSC) was used to detect total radioactivity recovery and HPLC/radio-detector for metabolite profiling in urine and bile. RESULTS The majority(73.6%)of the administered radioactivity was recovered in the first 24 h postdose with 48.3%in urine and 25.4%in faeces. It was cumulated to(84.7±6.8)%till 168 h. In BDC rats,29.3%of the dose was recovered in the bile 3 d post-dose. According to the peak area ratio determined by HPLC/radio-detector,only 4.7%and 9.5%of the radioactive dose were excreted as the parent drug in urine and bile,respectively,while the majority of the remaining radioactivity was excreted in the form of various metabolites. CONCLUSION Following oral administration in rats,trantinterol is completely absorbed,extensively metabolized and rapidly excreted mainly in urine as various metabolites.
ABSTRACT
La Enfermedad de Wilson es un trastorno autosómico recesivo causado por mutaciones en el genATP7B que producen anormalidad en el metabolismo del cobre, con acumulación de este elementoen distintos órganos y tejidos. El diagnóstico se basa en la combinación del cuadro clínico con diversaspruebas bioquímicas, pues ninguna de ellas, aisladamente, es diagnóstica. En la actualidad se cuentacon un tratamiento efectivo para esta enfermedad, basado en la utilización de quelantes del cobre,para movilizarlo de los sitios donde se acumula y promover su excreción, así como de zinc parabloquear su absorción intestinal. El trasplante hepático es el tratamiento de elección en los pacientescon hepatopatía fulminante, así como en los que llegan a la cirrosis descompensada. En esta revisiónse incluyen aspectos bioquímicos, genéticos, clínicos, diagnósticos y terapéuticos de esta enfermedad.
Wilsons disease: a reviewWilsons disease is an autosomal recessive disorder caused by mutations in the ATP7B gene thatlead to an abnormal metabolism of copper, resulting in the accumulation of this element inseveral organs and tissues. Its diagnosis is based on the combination of the clinical picture withvarious biochemical tests, neither one of which is, by itself, diagnostic of the disease. Presentlythere are effective treatments for EW based on the administration of chelating agents to promotemobilization of copper from the accumulation sites and its excretion. Zinc is also used in orderto block the intestinal absorption of copper. Liver transplantation is the treatment of choice inpatients with fulminating hepatitis, as well as in those with decompensated cirrhosis. This reviewincludes the following aspects of Wilsons disease: biochemical, genetic, clinical, diagnostic, andtherapeutic.